Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results
09 nov. 2017 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference
21 sept. 2017 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
08 sept. 2017 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results
09 août 2017 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a clinical-stage biopharmaceutical company using...
Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
07 août 2017 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
21 juil. 2017 14h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
19 juil. 2017 08h30 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results
11 mai 2017 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 11, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
05 mai 2017 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
28 mars 2017 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...